Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

The era of immunogenomics/immunopharmacogenomics.

Zewde M, Kiyotani K, Park JH, Fang H, Yap KL, Yew PY, Alachkar H, Kato T, Mai TH, Ikeda Y, Matsuda T, Liu X, Ren L, Deng B, Harada M, Nakamura Y.

J Hum Genet. 2018 Jul;63(8):865-875. doi: 10.1038/s10038-018-0468-1. Epub 2018 May 21. Review.

PMID:
29785006
2.

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment.

Ko TM, Kiyotani K, Chang JS, Park JH, Yew PY, Chen YT, Wu JY, Nakamura Y.

Hum Mol Genet. 2018 May 16. doi: 10.1093/hmg/ddy176. [Epub ahead of print]

3.

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ.

Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10.

4.

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.

Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y.

Clin Cancer Res. 2018 May 2. doi: 10.1158/1078-0432.CCR-18-0142. [Epub ahead of print]

PMID:
29720506
5.

Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.

Kato T, Matsuda T, Ikeda Y, Park JH, Leisegang M, Yoshimura S, Hikichi T, Harada M, Zewde M, Sato S, Hasegawa K, Kiyotani K, Nakamura Y.

Oncotarget. 2018 Jan 13;9(13):11009-11019. doi: 10.18632/oncotarget.24232. eCollection 2018 Feb 16.

6.

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer.

Ren L, Matsuda T, Deng B, Kiyotani K, Kato T, Park JH, Seiwert TY, Vokes EE, Agrawal N, Nakamura Y.

Oncotarget. 2017 Dec 19;9(3):3805-3814. doi: 10.18632/oncotarget.23454. eCollection 2018 Jan 9.

7.

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.

Kiyotani K, Chan HT, Nakamura Y.

Cancer Sci. 2018 Mar;109(3):542-549. doi: 10.1111/cas.13498. Epub 2018 Feb 14. Review.

8.

Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy.

Kiyotani K, Mai TH, Yamaguchi R, Yew PY, Kulis M, Orgel K, Imoto S, Miyano S, Burks AW, Nakamura Y.

J Hum Genet. 2018 Feb;63(2):239-248. doi: 10.1038/s10038-017-0364-0. Epub 2017 Nov 30.

PMID:
29192240
9.

Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers.

Kato T, Park JH, Kiyotani K, Ikeda Y, Miyoshi Y, Nakamura Y.

Oncotarget. 2017 Jun 28;8(37):62029-62038. doi: 10.18632/oncotarget.18790. eCollection 2017 Sep 22.

10.

p53-independent p21 induction by MELK inhibition.

Matsuda T, Kato T, Kiyotani K, Tarhan YE, Saloura V, Chung S, Ueda K, Nakamura Y, Park JH.

Oncotarget. 2017 Jun 15;8(35):57938-57947. doi: 10.18632/oncotarget.18488. eCollection 2017 Aug 29.

11.

Characterization of the cryoablation-induced immune response in kidney cancer patients.

Kato T, Iwasaki T, Uemura M, Nagahara A, Higashihara H, Osuga K, Ikeda Y, Kiyotani K, Park JH, Nonomura N, Nakamura Y.

Oncoimmunology. 2017 May 16;6(7):e1326441. doi: 10.1080/2162402X.2017.1326441. eCollection 2017.

12.

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer.

Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y, O'Donnell PH.

Eur Urol Focus. 2016 Oct;2(4):445-452. doi: 10.1016/j.euf.2015.09.007. Epub 2015 Oct 9.

13.

Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.

Mai T, Takano A, Suzuki H, Hirose T, Mori T, Teramoto K, Kiyotani K, Nakamura Y, Daigo Y.

Oncol Lett. 2017 Jul;14(1):283-292. doi: 10.3892/ol.2017.6125. Epub 2017 May 5.

14.

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.

Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert T, Cipriani N, Lingen M, Vokes E, Nakamura Y.

Clin Cancer Res. 2017 Aug 15;23(16):4897-4907. doi: 10.1158/1078-0432.CCR-17-0103. Epub 2017 Apr 25.

15.

Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.

Ikeda Y, Kiyotani K, Yew PY, Sato S, Imai Y, Yamaguchi R, Miyano S, Fujiwara K, Hasegawa K, Nakamura Y.

Oncol Rep. 2017 May;37(5):2603-2610. doi: 10.3892/or.2017.5536. Epub 2017 Mar 29.

16.

Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.

Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT.

Oncoimmunology. 2017 Jan 6;6(2):e1278330. doi: 10.1080/2162402X.2016.1278330. eCollection 2017.

17.

WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.

Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park JH, Matsuo Y, Lingen M, Suzuki T, Dohmae N, Hamamoto R, Nakamura Y.

Sci Rep. 2017 Jan 19;7:40664. doi: 10.1038/srep40664.

18.

PS01.05: Early and Persistent Oligoclonal T Cell Expansion Correlates with Durable Response to Anti-PD1 Therapy in NSCLC: Topic: Medical Oncology.

Olugbile S, Kiyotani K, Park JH, Hoffman P, Szeto L, Patel J, Vokes E, Nakamura Y.

J Thorac Oncol. 2016 Nov;11(11S):S272. doi: 10.1016/j.jtho.2016.09.041. Epub 2016 Oct 28. No abstract available.

19.

Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors.

Kiyotani K, Mai TH, Nakamura Y.

J Hum Genet. 2017 Mar;62(3):397-405. doi: 10.1038/jhg.2016.141. Epub 2016 Nov 24.

20.

Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).

Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca G.

Leuk Lymphoma. 2017 Apr;58(4):950-958. doi: 10.1080/10428194.2016.1219902. Epub 2016 Nov 17.

21.

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.

Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y.

Oncoimmunology. 2016 Jun 30;5(9):e1204507. eCollection 2016.

22.

Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors.

Nakakido M, Tamura K, Chung S, Ueda K, Fujii R, Kiyotani K, Nakamura Y.

Int J Oncol. 2016 Sep;49(3):868-76. doi: 10.3892/ijo.2016.3607. Epub 2016 Jul 6.

23.

Myasthenic crisis and polymyositis induced by one dose of nivolumab.

Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park JH, Nakamura Y, Ihn H.

Cancer Sci. 2016 Jul;107(7):1055-8. doi: 10.1111/cas.12961.

24.

WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.

Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R.

Oncotarget. 2016 Jul 5;7(27):42527-42538. doi: 10.18632/oncotarget.9897.

25.

Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer.

Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, Kanekiyo S, Shindo Y, Miyano S, Nakamura Y, Kiyotani K.

Oncol Lett. 2016 Jun;11(6):3643-3649. Epub 2016 Apr 19.

26.

Characterization of T-cell Receptor Repertoire in Inflamed Tissues of Patients with Crohn's Disease Through Deep Sequencing.

Chapman CG, Yamaguchi R, Tamura K, Weidner J, Imoto S, Kwon J, Fang H, Yew PY, Marino SR, Miyano S, Nakamura Y, Kiyotani K.

Inflamm Bowel Dis. 2016 Jun;22(6):1275-85. doi: 10.1097/MIB.0000000000000752.

PMID:
27135481
27.

Germline PARP4 mutations in patients with primary thyroid and breast cancers.

Ikeda Y, Kiyotani K, Yew PY, Kato T, Tamura K, Yap KL, Nielsen SM, Mester JL, Eng C, Nakamura Y, Grogan RH.

Endocr Relat Cancer. 2016 Mar;23(3):171-9. doi: 10.1530/ERC-15-0359. Epub 2015 Dec 23.

28.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H.

Clin Cancer Res. 2016 Jun 1;22(11):2734-43. doi: 10.1158/1078-0432.CCR-15-2361. Epub 2015 Dec 14.

29.

Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8+ T cells.

Liu X, Venkataraman G, Lin J, Kiyotani K, Smith S, Montoya M, Nakamura Y, Kline J.

Oncoimmunology. 2015 Feb 3;4(5):e1002728. eCollection 2015 May.

30.

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.

Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y.

Bone Marrow Transplant. 2015 Sep;50(9):1227-34. doi: 10.1038/bmt.2015.133. Epub 2015 Jun 8.

31.

Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.

Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, Campanile A, Yew PY, Ganshert C, Fujioka T, Steinberg GD, O'Donnell PH, Nakamura Y.

Clin Cancer Res. 2014 Dec 15;20(24):6605-17. doi: 10.1158/1078-0432.CCR-14-0257. Epub 2014 Oct 14.

32.

WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.

Saloura V, Cho HS, Kiyotani K, Alachkar H, Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, Nakamura Y, Hamamoto R.

Mol Cancer Res. 2015 Feb;13(2):293-304. doi: 10.1158/1541-7786.MCR-14-0292-T. Epub 2014 Oct 3.

33.

Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity.

Yamada A, Maeda K, Kiyotani K, Mushiroda T, Nakamura Y, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 23;3:e126. doi: 10.1038/psp.2014.23.

34.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

35.

Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring.

Aomori T, Fujita Y, Obayashi K, Sato H, Kiyotani K, Nakamura K, Nakamura T, Yamamoto K.

J Clin Pharm Ther. 2014 Jun;39(3):319-21. doi: 10.1111/jcpt.12135. Epub 2014 Feb 25.

PMID:
24612117
36.

Involvement of B3GALNT2 overexpression in the cell growth of breast cancer.

Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T.

Int J Oncol. 2014 Feb;44(2):427-34. doi: 10.3892/ijo.2013.2187. Epub 2013 Nov 27.

PMID:
24285400
37.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

38.

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.

Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y.

J Hum Genet. 2013 Jun;58(6):327-33. doi: 10.1038/jhg.2013.39. Epub 2013 May 9. Review.

PMID:
23657426
39.

Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin.

Ueng YF, Chen CC, Yamazaki H, Kiyotani K, Chang YP, Lo WS, Li DT, Tsai PL.

Drug Metab Pharmacokinet. 2013;28(3):229-38. Epub 2012 Dec 18.

40.

Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis.

Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto S, Miyano S, Nakamura Y, Sasa M, Shimada M, Katagiri T.

Int J Oncol. 2013 Feb;42(2):478-506. doi: 10.3892/ijo.2012.1744. Epub 2012 Dec 18.

PMID:
23254957
41.

A commentary on Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.

Kiyotani K, Katagiri T.

J Hum Genet. 2013 Feb;58(2):58. doi: 10.1038/jhg.2012.142. Epub 2012 Dec 6. No abstract available.

PMID:
23223009
42.

Cytochrome P450 2A6 phenotyping based on dietary caffeine intake in a Japanese population of non-smokers.

Kimura M, Shimizu M, Kiyotani K, Nakagawa K, Kamataki T, Yamazaki H.

Drug Metab Lett. 2012 Jun 1;6(2):67-72.

PMID:
22849705
43.

Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway.

Nakada T, Kiyotani K, Iwano S, Uno T, Yokohira M, Yamakawa K, Fujieda M, Saito T, Yamazaki H, Imaida K, Kamataki T.

J Toxicol Sci. 2012;37(3):555-63.

44.

Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein.

Irie T, Kiyotani K, Igarashi T, Yoshida A, Sakaguchi T.

J Virol. 2012 Jul;86(13):7136-45. doi: 10.1128/JVI.06705-11. Epub 2012 Apr 24.

45.

A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.

Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, Ina S, Kihara C, Kimura Y, Yamaue H, Hirata K, Nakamura Y, Zembutsu H.

Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba. Erratum in: Pharmacogenet Genomics. 2014 Oct;24(10):530.

PMID:
22293537
46.

Identification of a functional variant in SPLUNC1 associated with nasopharyngeal carcinoma susceptibility among Malaysian Chinese.

Yew PY, Mushiroda T, Kiyotani K, Govindasamy GK, Yap LF, Teo SH, Lim PV, Govindaraju S, Ratnavelu K, Sam CK, Yap YY, Khoo AS, Pua KC, Nakamura Y; Malaysian NPC Study Group, Ng CC.

Mol Carcinog. 2012 Oct;51 Suppl 1:E74-82. doi: 10.1002/mc.21857. Epub 2011 Dec 27.

PMID:
22213098
47.

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.

Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, Tanigawara Y, Imamura CK, Flockhart DA, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.

Hum Mol Genet. 2012 Apr 1;21(7):1665-72. doi: 10.1093/hmg/ddr597. Epub 2011 Dec 16.

PMID:
22180457
48.

Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.

Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H.

Drug Metab Pharmacokinet. 2012;27(1):122-31. Epub 2011 Nov 1. Review.

49.

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.

Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H.

Breast Cancer Res Treat. 2012 Jan;131(1):137-45. doi: 10.1007/s10549-011-1777-7. Epub 2011 Sep 23.

PMID:
21947681
50.

CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.

Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.

Eur J Clin Pharmacol. 2012 Mar;68(3):267-71. doi: 10.1007/s00228-011-1118-0. Epub 2011 Sep 8.

PMID:
21901344

Supplemental Content

Loading ...
Support Center